Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics entities : Beigene, ltd. save search
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -1.58%
H: 11.22%
C: 11.16%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.36%
H: 3.65%
C: 3.35%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.5%
H: 3.18%
C: 3.12%
conference therapeutics
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
Published: 2023-11-21 (Crawled : 19:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.37%
H: 0.92%
C: -0.2%
partnership therapeutics
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 4.14%
H: 6.22%
C: 1.41%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.5%
H: 2.69%
C: -0.09%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.94%
H: 1.82%
C: 1.25%
business therapeutics financial results
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
Published: 2023-10-06 (Crawled : 12:30) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.62%
H: 1.06%
C: 0.25%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.73%
H: 2.07%
C: 1.64%
acquisition therapeutics
Intrahepatic Cholangiocarcinoma Market to Grow Rapidly During the Study Period (2019-2032), Examines DelveInsight | Key Players - Virogin Biotech, Syndax, Delcath Systems, AstraZeneca, Amgen, Jazz, BeiGene
Published: 2023-09-20 (Crawled : 21:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.47%
H: 0.0%
C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.39%
H: 1.03%
C: -0.59%
RLAY | $5.96 -2.46% -2.52% 2.4M
|
Health Technology
|
| O: -2.04%
H: 0.87%
C: -0.46%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.22%
H: 0.25%
C: -2.37%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -2.14%
H: 0.25%
C: -0.49%
study market
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
Published: 2023-09-01 (Crawled : 13:30) - prnewswire.com
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: -0.35%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.36%
H: 2.44%
C: 0.3%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.91%
H: 0.14%
C: -0.76%
resolve acquisition therapeutics
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
Published: 2023-05-09 (Crawled : 13:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 27.58%
H: 110.1%
C: 18.47%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -3.11%
H: 0.6%
C: -0.14%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.01%
H: 0.34%
C: -0.09%
disease collaboration therapeutics
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-17 (Crawled : 19:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 1.32%
H: 3.79%
C: -0.12%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.83%
H: 1.34%
C: -0.08%
bgb-3245 association tumors cancer research meeting
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-17 (Crawled : 19:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 1.32%
H: 3.79%
C: -0.12%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.83%
H: 1.34%
C: -0.08%
association tumors cancer research meeting
Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
Published: 2023-01-11 (Crawled : 12:20) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: -1.94%
H: 6.44%
C: 4.3%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: -1.02%
conference therapeutics leap
Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.51%
H: 2.35%
C: 0.31%
pt199 therapeutics agreement
Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference
Published: 2022-11-21 (Crawled : 13:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 2.33%
H: 2.6%
C: -4.81%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -2.27%
H: 2.08%
C: -1.95%
conference therapeutics leap
Esophageal Squamous Cell Carcinoma Pipeline Looks Promising as 45+ Companies Working in the Domain, Assesses DelveInsight
Published: 2022-10-25 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.03%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.4%
H: 1.68%
C: 1.38%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: 0.0%
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: -3.0%
H: 7.63%
C: 2.55%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.72%
C: -0.1%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.7%
H: 5.5%
C: 3.97%
BCEL P | $0.0761 0.0% 350K
|
Health Technology
|
| O: 2.76%
H: 1.34%
C: 0.0%
companies cell carcinoma
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: -1.14%
H: 4.6%
C: 3.24%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 4.91%
H: 6.28%
C: 2.04%
dkn-01 treatment therapeutics leap cancer study
Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
Published: 2022-10-12 (Crawled : 14:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 0.7%
H: 2.79%
C: 0.24%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.77%
H: 20.74%
C: 17.3%
dkn-01 treatment therapeutics leap cancer study
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 0.22%
H: 0.39%
C: -2.49%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.17%
H: 0.08%
C: -0.29%
dkn-01 preclinical meeting therapeutics plus leap cancer study
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress
Published: 2022-09-04 (Crawled : 00:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
| Email alert
Add to watchlist
dkn-01 tecentriq therapeutics plus leap study
Antengene Announces Interim 2022 Financial Results and Provides Corporate Update
Published: 2022-08-31 (Crawled : 01:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.99%
H: 1.96%
C: -0.59%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.3%
H: 1.98%
C: 0.39%
update results
BioSpace Movers & Shakers: Tessera, Tessa, Adial and More
Published: 2022-08-26 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.52%
H: 0.0%
C: 0.0%
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -2.33%
H: 0.2%
C: -4.15%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 4.37%
H: 3.46%
C: -1.39%
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: -0.45%
H: 1.36%
C: -5.43%
BioSpace Movers & Shakers: Tessera, Vektor, Frontier, Celsius and More
Published: 2022-08-26 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.52%
H: 0.0%
C: 0.0%
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -2.33%
H: 0.2%
C: -4.15%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 4.37%
H: 3.46%
C: -1.39%
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: -0.45%
H: 1.36%
C: -5.43%
celsius
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.